Companies · Biotechnology

CoreLab Partners, Inc.

PRINCETON · Biotechnology

Diligence memoA one-page analyst read on CoreLab Partners, Inc. — recommendation, valuation, rhythm, risks.
$15.7M
Total raised · real
3
Rounds
0.5×
Latest step-up
Top 37%
Sector rank · raised
Series A
Latest stage · inferred · Wed Sep 15 2010 00:00:00 GMT+0000 (Coordinated Universal Time)

CoreLab Partners, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.57× the median modeled value of Series A Biotechnology companies in 2010–2012 (92 peers) — value vs value, same stage and era.
Dormant
  • Last raise 15.8 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

CoreLab Partners, Inc. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
15.8 yr record
Peak capital year was 2010 with $15.7M across 3 filings.
Market position
ahead of 64% of Biotechnology peers
Capital scale is ahead of 64% of Biotechnology peers; modeled value is above 77% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2010: $15.7M across 3 filings.
  • Largest single filing was $8.7M on 2010-09-15.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

CoreLab Partners, Inc. is one of 4291 Biotechnology companies tracked from PRINCETON. By capital raised it ranks mid-pack (ahead of 64% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2010-09-15 Raised $8.7M (real) Modeled valuation $315M (est)$8.7M$315MSeries A2010Series A · 2010-09-15 Raised $4.7M (real) Modeled valuation $170M (est)$4.7M$170MSeries A2010Seed · 2010-09-15 Raised $2.3M (real) Modeled valuation $101M (est)$2.3M$101MSeed2010+$4.7M+$2.3MCumulative $16M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$8.7M · 2010
Series A extension$4.7M · 2010
Bridge · Series A-stage$2.3M · 2010smaller follow-on

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$315.0M
Base estimate est.
$9.5M
Conservative case
$1.7B
Upside case
$39.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $315.0M · 2010-09-152010Series A · modeled $170.4M · 2010-09-15Seed · modeled $101.1M · 2010-09-152010
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
15.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
0 mo
Avg between rounds
Capital velocity
15.8 yr
On record since
2010
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 2.2× above median
This company$15.7M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.4× of median
This company$2.3M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 4.9× above median
This company$315.0M
Sector median$64.2M

Raised more than 64% of sector peers (real $). Modeled value above 77% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #29 of 92.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)Tobira Therapeutics, Inc. · Series A Raised $23.2M · modeled $513.3M (est)Neoprobe Corp · Series A Raised $14.0M · modeled $506.1M (est)Akebia Therapeutics, Inc. · Series A Raised $25.9M · modeled $504.1M (est)Adimab, LLC · Series A Raised $13.8M · modeled $499.5M (est)Elevation Pharmaceuticals Inc · Series A Raised $27.4M · modeled $448.3M (est)Mnemosyne Pharmaceuticals Inc · Series A Raised $24.0M · modeled $445.8M (est)Macrogenics Inc · Series A Raised $12.0M · modeled $434.4M (est)Neurologica Corp · Series A Raised $17.0M · modeled $433.8M (est)Bodymedia Inc · Series A Raised $20.1M · modeled $429.9M (est)Peloton Therapeutics, Inc. · Series A Raised $13.7M · modeled $423.0M (est)Seahorse Bioscience Inc · Series A Raised $20.7M · modeled $410.2M (est)Stemgent, Inc. · Series A Raised $37.9M · modeled $408.5M (est)CoreLab Partners, Inc. (this company) Raised $15.7M · modeled $315.0M (est)CoreLab Partners, Inc.
CompanyStageRaised · realValue · estvs peer med.
Tobira Therapeutics, Inc.Series A$23.2M$513.3M2.56×
Neoprobe CorpSeries A$14.0M$506.1M2.53×
Akebia Therapeutics, Inc.Series A$25.9M$504.1M2.52×
Adimab, LLCSeries A$13.8M$499.5M2.50×
Elevation Pharmaceuticals IncSeries A$27.4M$448.3M2.24×
Mnemosyne Pharmaceuticals IncSeries A$24.0M$445.8M2.23×
Macrogenics IncSeries A$12.0M$434.4M2.17×
Neurologica CorpSeries A$17.0M$433.8M2.17×
Bodymedia IncSeries A$20.1M$429.9M2.15×
Peloton Therapeutics, Inc.Series A$13.7M$423.0M2.11×
Seahorse Bioscience IncSeries A$20.7M$410.2M2.05×
Stemgent, Inc.Series A$37.9M$408.5M2.04×
CoreLab Partners, Inc. this companySeries A$15.7M$315.0M1.57×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$8.7M2010-09-15$39.6M$315.0M90%
Series A$4.7M2010-09-15$21.4M$170.4M90%
Seed$2.3M2010-09-15$11.4M$101.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$8.7M2010-09-15
    • First recorded raise — entered as Series A.
  2. Series A$4.7M2010-09-15
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.8× smaller than the prior — bridge or down round.
  3. Seed$2.3M2010-09-15
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.1× smaller than the prior — bridge or down round.
Intelligence
Modeled next raise
$2.3M
Modeled next size est.range $2.3M$3.6M
0.5×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Eugene D. Hill4 other2010-09
Herbert H. Hooper2 other2010-09
Denis J. Manginelli1 other2010-09
Richard A. Charpie1 other2010-09
Andrew T. Jay2010-09
Michael Woehler2010-09
Suzanne E. MacCormack2010-09
Registry & provenance

CoreLab Partners, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1501878
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Aeglea BioTherapeutics Holdings, LLCBiotechnologySeries A$15.8M$387.1Msame sector · same stage
Impliant IncBiotechnologySeries A$15.6M$240.5Msame sector · same stage
Arsenal Medical, Inc.BiotechnologySeries A$16.0M$217.6Msame sector · same stage
Cocrystal Discovery IncBiotechnologySeries A$15.2M$271.1Msame sector · same stage
Kanyos Bio, Inc.BiotechnologySeries A$16.4M$376.0Msame sector · same stage
Viewpoint Molecular Targeting, Inc.BiotechnologySeries A$15.0M$427.0Msame sector · same stage
DoubleRainbow Biosciences Inc.BiotechnologySeries A$15.0M$309.5Msame sector · same stage
Genethera IncBiotechnologySeries A$15.0M$354.6Msame sector · same stage
Frequently asked
How much funding has CoreLab Partners, Inc. raised?
CoreLab Partners, Inc. has raised approximately $15.7M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is CoreLab Partners, Inc.'s estimated valuation?
Provath's modeled valuation for CoreLab Partners, Inc. is approximately $315.0M (modeled range $9.5M–$1.7B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is CoreLab Partners, Inc. at?
CoreLab Partners, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Wed Sep 15.
What does CoreLab Partners, Inc. do and where is it based?
CoreLab Partners, Inc. operates in the Biotechnology sector, based in PRINCETON.
Explore related

See where CoreLab Partners, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at CoreLab Partners, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.